CAR T-cell Therapy in 2022: What You Need to Know

Caron Jacobson, MD, Dana-Farber Cancer Institute, Boston, MA

Recorded on January 4, 2022


Caron Jacobson, MD
Caron Jacobson, MD
Assistant Professor of Medicine
Harvard Medical School
Medical Director
Immune Effector Cell Therapy Program
Dana-Farber Cancer Institute
Boston, MA

As we move into 2022, chimeric antigen receptor (CAR) T-cell therapy continues to be a very exciting and effective treatment option for some blood cancer patients. In this episode, Dr. Caron Jacobson, Assistant Professor of Medicine, Harvard Medical School, Medical Director, Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute in Boston, MA, discusses updates in CAR T-cell therapy, including progress in managing toxicities, barriers to treatment, CAR T structure and manufacturing, other practical issues such as determining the best treatment option for patients facing serious disease, and future directions. Tune in to learn more!

This podcast episode is supported by Bristol Myers Squibb; CRISPR Therapeutics; Kite, a Gilead Company and Novartis Pharmaceuticals Corporation.

Leave a Reply

Your email address will not be published. Required fields are marked *